{"id":19654,"date":"2023-08-23T09:12:30","date_gmt":"2023-08-23T07:12:30","guid":{"rendered":"https:\/\/ggba.swiss\/?p=19654"},"modified":"2023-08-24T17:06:17","modified_gmt":"2023-08-24T15:06:17","slug":"nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/","title":{"rendered":"Nanomedicine pioneer Nanobacterie achieves remarkable patent ranking"},"content":{"rendered":"\n<p>Nanomedicine, with its revolutionary use of nanoscale materials, is redefining the boundaries of medical innovation. Leading this transformation is AlphaOnco Swiss, the subsidiary of the renowned French company <a href=\"http:\/\/www.nanobacterie.fr\/?page_id=177&amp;lang=en\">Nanobacterie<\/a>.<\/p>\n\n\n\n<p>Despite Nanobacterie&#8217;s modest size, it swiftly garnered accolades for its progressive work in the realm of nanomedicine-based cancer therapeutics. The targeted methodology of nanomedicine ensures therapeutic agents directly reach the disease site, amplifying the drug&#8217;s efficacy while curbing side effects. Building upon Nanobacterie&#8217;s foundational research, AlphaOnco Swiss seeks to exploit nanoparticles&#8217; potential to craft efficacious oncological solutions. This molecular and cellular tailoring of treatments doesn&#8217;t just elevate the standard of care but holds the promise of significantly better patient outcomes.<\/p>\n\n\n\n<p>The prowess of Nanobacterie recently drew recognition when the distinguished IP firm, <a href=\"https:\/\/www.marks-clerk.com\/insights\/articles\/nanomedicine-a-retrospective-and-a-glimpse-into-the-future\/\">Marks and Clerk<\/a>, placed it at an impressive fourth position for its volume of patents in nanomedicine. This accolade is particularly notable given the competitive field of medical research. Nanobacterie&#8217;s success, as the sole small entity with a lean team of fewer than ten to secure such a commendable ranking, underscores the relentless spirit of innovation that fuels its endeavors.<\/p>\n\n\n\n<p>AlphaOnco Swiss is currently actively courting investors to secure the necessary financing, propelling its pioneering endeavors further into the realm of innovative cancer treatments.<\/p>\n\n\n\n<figure class=\"wp-block-embed aligncenter is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" title=\"Western Switzerland for Precision Oncology Companies (AlphaOnco Swiss)\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/tjQbZa9mw9g?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\">A longstanding collaboration with Switzerland<\/h4>\n\n\n\n<p>Edouard Alphand\u00e9ry, CEO of Nanobacterie and founder of AlphaOnco Swiss, has highlighted the company&#8217;s longstanding collaboration with Switzerland. Given the country&#8217;s strong inclination towards innovation and biotechnological research, Switzerland provided a natural ground for AlphaOnco Swiss&#8217;s ambitions. The company\u2019s connection with Swiss institutions spans over six years, making the decision to establish a subsidiary there logical and strategic. When deciding on the specific location within Switzerland, Alphand\u00e9ry approached <a href=\"https:\/\/ggba.swiss\/en\/services\/\">GGBa<\/a> and the <a href=\"https:\/\/valais-economy.ch\/?_gl=1%2A1h0eorb%2A_ga%2AMTI1NzMzNzIzOC4xNjkwOTg1MzIx%2A_ga_XXZPGLFWVX%2AMTY5Mjc3NDUyNC41LjEuMTY5Mjc3NDYxNi4wLjAuMA..\">Economic Promotion Valais<\/a>.<\/p>\n\n\n\n<p>The local agencies\u2019 guidance led him to the <a href=\"https:\/\/www.bioark.ch\/en\/\">BioArk<\/a> in Monthey (canton of Valais), which is renowned for its robust support to start-ups. Being at BioArk, AlphaOnco Swiss leverages Swiss regulatory expertise, ensuring their innovative treatment aligns with quality and safety standards. According to Alphand\u00e9ry, this location not only streamlined the collaboration between France and Switzerland, but also allowed AlphaOnco Swiss to benefit from the regulatory strengths that Switzerland brings to the table.<\/p>\n\n\n\n<p>Building on Nanobacterie&#8217;s achievements, AlphaOnco Swiss is primed to further the trajectory of research and innovation in nanomedicine-oriented cancer care. With Nanobacterie&#8217;s robust patent repertoire bolstering its position, AlphaOnco Swiss is well-poised to attract further investments and form strategic alliances. As cancer continues to challenge the global community, AlphaOnco Swiss is an example of how nanomedicine can usher in revolutionary treatments. From their base in Valais, they are spearheading advances that have the medical world and patients excited for the next breakthrough.<\/p>\n\n\n\n<figure class=\"wp-block-embed aligncenter is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" title=\"BioArk (What Is Series)\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/UI1tkcnVCu0?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Drawing from the achievements of its parent company, Nanobacterie, Valais-based AlphaOnco Swiss stands at the forefront of innovative nanomedicine-based cancer treatments.<\/p>\n","protected":false},"author":6,"featured_media":19655,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,894,883,911,901],"class_list":["post-19654","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-financing","tag-oncology","tag-pharma","tag-technology-park"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanomedicine pioneer Nanobacterie excels in patent ranking<\/title>\n<meta name=\"description\" content=\"Valais-based AlphaOnco Swiss, a subsidiary of French company Nanobacterie, has pioneered advances in nanomedicine-based cancer treatments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanomedicine pioneer Nanobacterie excels in patent ranking\" \/>\n<meta property=\"og:description\" content=\"Valais-based AlphaOnco Swiss, a subsidiary of French company Nanobacterie, has pioneered advances in nanomedicine-based cancer treatments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-23T07:12:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-24T15:06:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2023\/08\/Nanobacterie_2360x1622-1024x704.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"704\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Nanomedicine pioneer Nanobacterie achieves remarkable patent ranking\",\"datePublished\":\"2023-08-23T07:12:30+00:00\",\"dateModified\":\"2023-08-24T15:06:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/\"},\"wordCount\":477,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/08\/Nanobacterie_2360x1622.jpeg\",\"keywords\":[\"Biotech\",\"Financing\",\"Oncology\",\"Pharma\",\"Technology Park\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/\",\"url\":\"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/\",\"name\":\"Nanomedicine pioneer Nanobacterie excels in patent ranking\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/08\/Nanobacterie_2360x1622.jpeg\",\"datePublished\":\"2023-08-23T07:12:30+00:00\",\"dateModified\":\"2023-08-24T15:06:17+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Valais-based AlphaOnco Swiss, a subsidiary of French company Nanobacterie, has pioneered advances in nanomedicine-based cancer treatments.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/08\/Nanobacterie_2360x1622.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/08\/Nanobacterie_2360x1622.jpeg\",\"width\":2360,\"height\":1622,\"caption\":\"Backed by its parent company Nanobacterie's fourth-place in nanomedicine patent rankings by Marks and Clerk, AlphaOnco Swiss channels the synergy of Franco-Swiss collaboration to bring forth groundbreaking cancer treatments.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanomedicine pioneer Nanobacterie achieves remarkable patent ranking\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanomedicine pioneer Nanobacterie excels in patent ranking","description":"Valais-based AlphaOnco Swiss, a subsidiary of French company Nanobacterie, has pioneered advances in nanomedicine-based cancer treatments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/","og_locale":"en_US","og_type":"article","og_title":"Nanomedicine pioneer Nanobacterie excels in patent ranking","og_description":"Valais-based AlphaOnco Swiss, a subsidiary of French company Nanobacterie, has pioneered advances in nanomedicine-based cancer treatments.","og_url":"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-08-23T07:12:30+00:00","article_modified_time":"2023-08-24T15:06:17+00:00","og_image":[{"width":1024,"height":704,"url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/08\/Nanobacterie_2360x1622-1024x704.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Nanomedicine pioneer Nanobacterie achieves remarkable patent ranking","datePublished":"2023-08-23T07:12:30+00:00","dateModified":"2023-08-24T15:06:17+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/"},"wordCount":477,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/08\/Nanobacterie_2360x1622.jpeg","keywords":["Biotech","Financing","Oncology","Pharma","Technology Park"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/","url":"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/","name":"Nanomedicine pioneer Nanobacterie excels in patent ranking","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/08\/Nanobacterie_2360x1622.jpeg","datePublished":"2023-08-23T07:12:30+00:00","dateModified":"2023-08-24T15:06:17+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Valais-based AlphaOnco Swiss, a subsidiary of French company Nanobacterie, has pioneered advances in nanomedicine-based cancer treatments.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/08\/Nanobacterie_2360x1622.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/08\/Nanobacterie_2360x1622.jpeg","width":2360,"height":1622,"caption":"Backed by its parent company Nanobacterie's fourth-place in nanomedicine patent rankings by Marks and Clerk, AlphaOnco Swiss channels the synergy of Franco-Swiss collaboration to bring forth groundbreaking cancer treatments."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Nanomedicine pioneer Nanobacterie achieves remarkable patent ranking"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/19654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=19654"}],"version-history":[{"count":5,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/19654\/revisions"}],"predecessor-version":[{"id":19695,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/19654\/revisions\/19695"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/19655"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=19654"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=19654"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=19654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}